Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 studyYuankai Shi, Chuan Gu, Xiaodong Zhang et al.|The Lancet Respiratory Medicine|2022Cited by 235
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG StudyYuankai Shi, Chuan Gu, Gongyan Chen et al.|Journal of Thoracic Oncology|2022Cited by 79
Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancerYuankai Shi, Nan Ge, Gongyan Chen et al.|The Lancet Regional Health - Western Pacific|2024Cited by 7
Central nervous system efficacy of furmonertinib versus gefitinib in patients with non–small cell lung cancer with epidermal growth factor receptor mutations: Results from FURLONG study.Gongyan Chen, Yuankai Shi, Xiang Wang et al.|Journal of Clinical Oncology|2022Cited by 5